EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prophylactic Treatment with Baloxavir Protects Mice from Lethal Infection with Influenza A and B Viruses

Keita Fukao, Takeshi Noshi, Shinya Shano, Kaoru Baba, Kenji Sato, Masashi Sakuramoto, Naohisa Kitade, Hideki Tanioka, Shinji Kusakabe iD, Takao Shishido iD

Viruses · 2023

DOI: 10.3390/v15112264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Keita Fukao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shionogi & Co., Ltd., Osaka 561-0825, Japan. Hauptthemen laut MEDLINE: Influenza, Human, Herpesvirus 1, Cercopithecine, Influenza A Virus, H1N1 Subtype, Thiepins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shionogi and Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Influenza remains a worldwide health concern. Antiviral drugs are considered as one of the useful options for its prevention as a complementary measure to vaccination. Baloxavir acid selectively inhibits the cap-dependent endonuclease of influenza viruses and exhibits marked viral titre reduction in patients. Here, we describe the prophylactic potency of baloxavir acid against lethal infection with influenza A and B viruses in mice. BALB/c mice were subcutaneously administered once with baloxavir acid suspension, or orally administered once daily for 10 days with oseltamivir phosphate solution at human relevant doses. Next, the mice were intranasally inoculated with A/PR/8/34 (H1N1) or B/Hong Kong/5/72 strain at 24 to 96 h after the initial dosing. Prophylactic treatment with the antiviral drugs significantly reduced the lung viral titres and prolonged survival time. In particular, baloxavir acid showed a greater suppressive effect on lung viral titres compared to oseltamivir phosphate. In this model, baloxavir acid maintained significant prophylactic effects against influenza A and B virus infections when the plasma concentration at the time of infection was at least 0.88 and 3.58 ng/mL, respectively. The significant prophylactic efficacy observed in our mouse model suggests the potential utility of baloxavir marboxil for prophylaxis against influenza in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanHerpesvirus 1, CercopithecineInfluenza A Virus, H1N1 SubtypeThiepinsHumansAnimalsMiceOseltamivirOxazinesPyridinesAntiviral AgentsMice, Inbred BALB CPhosphatesDibenzothiepinsMorpholinesPyridonesTriazines

Stichwörter der Autor:innen

baloxavir acidbaloxavir marboxilcap-dependent endonuclease inhibitorinfluenza virusoseltamivir phosphateprophylaxis

Substanzen

OseltamivirOxazinesPyridinesThiepinsAntiviral AgentsPhosphatesbaloxavirDibenzothiepinsMorpholinesPyridones

Autor:innen und Institutionen

  • Shionogi & Co., Ltd., Osaka 561-0825, Japan.
  • Shionogi TechnoAdvance Research, Co., Ltd., Osaka 561-0825, Japan.

ORCID-Profile: Shinji Kusakabe, Takao Shishido

Förderung

  • Shionogi and Co., Ltd.

Zitieren

APA

Fukao, K., Noshi, T., Shano, S., Baba, K., Sato, K., Sakuramoto, M., Kitade, N., Tanioka, H., Kusakabe, S., & Shishido, T. (2023). Prophylactic Treatment with Baloxavir Protects Mice from Lethal Infection with Influenza A and B Viruses. Viruses. https://doi.org/10.3390/v15112264

Vancouver

Fukao K, Noshi T, Shano S, Baba K, Sato K, Sakuramoto M, et al. Prophylactic Treatment with Baloxavir Protects Mice from Lethal Infection with Influenza A and B Viruses. Viruses. 2023. doi:10.3390/v15112264

BibTeX
@article{Fukao2023,
  author = {Fukao, Keita and Noshi, Takeshi and Shano, Shinya and Baba, Kaoru and Sato, Kenji and Sakuramoto, Masashi and Kitade, Naohisa and Tanioka, Hideki and Kusakabe, Shinji and Shishido, Takao},
  title = {Prophylactic Treatment with Baloxavir Protects Mice from Lethal Infection with Influenza A and B Viruses},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15112264}
}
Kostenlos starten →